Re: Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients with Intermediate- or Poor-Risk Germ Cell Tumors Editorial Comment

被引：0
|
作者：
Richie, Jerome P.
机构：
来源：
JOURNAL OF UROLOGY | 2017年 / 198卷 / 02期
关键词：
D O I：
10.1016/j.juro.2017.05.023
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：257 / 257
页数：1
相关论文
共 50 条
  • [21] Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors:: a phase II study
    Mardiak, J
    Sálek, T
    Sycová-Milá, Z
    Obertová, J
    Hlavatá, Z
    Mego, M
    Recková, M
    Koza, I
    NEOPLASMA, 2005, 52 (06) : 497 - 501
  • [22] A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma
    Reinhorn, Daniel
    Sarfaty, Michal
    Leshno, Moshe
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    ONCOLOGIST, 2019, 24 (03): : 366 - 371
  • [23] COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLAND
    Oniangue-Ndza, C.
    Schneider, R.
    Malcolm, B.
    May, J.
    Gooden, K. M.
    Klijn, S.
    Cakar, E.
    VALUE IN HEALTH, 2019, 22 : S462 - S462
  • [24] COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN ITALY
    Di Rienzo, P.
    Zarrelli, L.
    Mennini, F. S.
    Marcellusi, A.
    Bini, C.
    Malcolm, B.
    May, J.
    Gooden, K. M.
    Van de Wetering, G.
    van Carroll, Smith L. E.
    VALUE IN HEALTH, 2019, 22 : S469 - S469
  • [25] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE
    Branchoux, S.
    Negrier, S.
    de Peretti, C.
    Malcolm, B.
    May, J.
    Marie, L.
    Gaudin, A. F.
    Klijn, S.
    Ignacio, T. J.
    VALUE IN HEALTH, 2019, 22 : S477 - S477
  • [26] STABILITY OF LIFETIME OVERALL SURVIVAL ESTIMATES OF NIVOLUMAB plus IPILIMUMAB IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA
    Cakar, E.
    May, J.
    Malcolm, B.
    Gooden, K. M.
    Klijn, S.
    VALUE IN HEALTH, 2019, 22 : S517 - S518
  • [27] re: Genetic Determinants of Cisplatin Resistance in Patients with Advanced Germ Cell Tumors Editorial Comment
    Richie, Jerome P.
    JOURNAL OF UROLOGY, 2017, 198 (04): : 746 - 746
  • [28] High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors
    Motzer, RJ
    Mazumdar, M
    Bajorin, DF
    Bosl, GJ
    Lyn, P
    Vlamis, V
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (07) : 2546 - 2552
  • [29] ALTERNATING CYCLES OF ETOPOSIDE PLUS CISPLATIN AND VAB-6 IN THE TREATMENT OF POOR-RISK PATIENTS WITH GERM-CELL TUMORS
    BOSL, GJ
    GELLER, NL
    VOGELZANG, NJ
    CAREY, R
    AUMAN, J
    WHITMORE, WF
    HERR, H
    MORSE, M
    SOGANI, P
    CHAN, E
    JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (03) : 436 - 440
  • [30] First-line combination chemotherapy with etoposide, ifosfamide and cisplatin for the treatment of disseminated germ cell cancer: Efficacy and feasibility in current clinical practice
    Fujiwara, Motohiro
    Tanaka, Hajime
    Yuasa, Takeshi
    Komai, Yoshinobu
    Oguchi, Tomohiko
    Fujiwara, Ryo
    Numao, Noboru
    Yamamoto, Shinya
    Fujii, Yasuhisa
    Fukui, Iwao
    Yonese, Junji
    INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (09) : 920 - 926
12345